Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma (2015)

Peer-Reviewed Study · Tier 1 — Primary Document · Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. · December 24, 2015

Schaapveld M et al., 2015-12-24: Dutch cohort of 3,905 five-year Hodgkin lymphoma survivors treated 1965-2000. Second cancers occurred at 4.6 times the general-population rate and cumulative incidence reached 48.5% at 40 years.

the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5)

Abstract (Results)

Schaapveld M et al., 2015-12-24: Dutch cohort of 3,905 five-year Hodgkin lymphoma survivors treated 1965-2000. Second cancers occurred at 4.6 times the general-population rate and cumulative incidence reached 48.5% at 40 years. Funded by the Dutch Cancer Society (stated in the abstract). Cohort, not a trial; comparator is general-population cancer incidence for the SIR and treatment subgroups within the cohort for hazard ratios. The book's '30 to 40 year cumulative incidence' matches the shape of this finding but the paper's headline is 48.5% at 40 years, not a 30-40% figure. Attribution split: a cumulative procarbazine dose of 4.3 g/m2 or more was associated with a LOWER breast-cancer risk (HR 0.57) but a HIGHER GI-cancer risk (HR 2.70); breast-cancer risk was lower with less extensive radiotherapy fields (HR 0.37). Full text paywalled; funding/COI read from the abstract only.